Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.

Am J Gastroenterol. 2014 Aug;109(8):1250-6. doi: 10.1038/ajg.2014.146. Epub 2014 Jun 10.

PMID:
24913041
2.

A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.

Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, van den Brink GR, DʼHaens GR.

Inflamm Bowel Dis. 2017 Apr;23(4):650-660. doi: 10.1097/MIB.0000000000001043.

PMID:
28195852
3.

Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.

Benmassaoud A, Al-Taweel T, Sasson MS, Moza D, Strohl M, Kopylov U, Paradis-Surprenant L, Almaimani M, Bitton A, Afif W, Lakatos PL, Bessissow T.

Dig Dis Sci. 2018 May;63(5):1302-1310. doi: 10.1007/s10620-017-4874-6. Epub 2017 Dec 14.

PMID:
29243105
4.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.

Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2017 Jun;23(6):976-985. doi: 10.1097/MIB.0000000000001072.

PMID:
28333755
5.

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.

Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, Bracaglia C, Marafon DP, Pastore S, Parentin F, Simonini G, De Libero C, Falcini F, Petaccia A, Filocamo G, De Marco R, La Torre F, Guerriero S, Martino S, Comacchio F, Muratore V, Martini G, Vittadello F, Zulian F.

J Rheumatol. 2018 Apr 15. pii: jrheum.171006. doi: 10.3899/jrheum.171006. [Epub ahead of print]

6.

Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.

Bodini G, Giannini EG, Savarino V, Del Nero L, Lo Pumo S, Brunacci M, De Bortoli N, Jain A, Tolone S, Savarino E.

Dig Liver Dis. 2018 May;50(5):452-456. doi: 10.1016/j.dld.2017.11.008. Epub 2017 Nov 27.

PMID:
29274766
7.

The Kinetics of Anti-Drug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immuno-Mediated Disorders.

Francesca N, Alessandra V, Sara P, Daniele C, Monica M, Ginevra F, Siro B, Francesca P, Sergio R, Enrico M, Andrea M.

J Allergy Clin Immunol Pract. 2018 Apr 13. pii: S2213-2198(18)30278-2. doi: 10.1016/j.jaip.2018.04.007. [Epub ahead of print]

PMID:
29660428
8.

Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants.

Kattah MG, Milush JM, Burt T, McCabe RP Jr, Whang MI, Ma A, Mahadevan U.

Clin Transl Gastroenterol. 2018 Apr 3;9(4):143. doi: 10.1038/s41424-018-0018-3.

9.

Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.

Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T.

Inflamm Bowel Dis. 2018 Apr 13. doi: 10.1093/ibd/izy044. [Epub ahead of print]

PMID:
29668893
10.

Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.

Govani SM, Noureldin M, Higgins PDR, Heisler M, Saini SD, Stidham RW, Waljee JF, Waljee AK.

Am J Gastroenterol. 2018 Feb;113(2):276-282. doi: 10.1038/ajg.2017.438. Epub 2017 Dec 12.

PMID:
29231192

Supplemental Content

Support Center